ArticleCancer discovery2017
Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers.
0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed
10.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
91 citing papers in PubMed, 127 citations in OpenAlex.
- Subclonal Complete Loss of CDKN1B as a Common Genomic Alteration in Prostate Cancer: Associations With Race and Prostate Cancer Outcomes.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2026Article
- Divergent effects of PLA2G7 on prostate cancer biochemical recurrence in European American and African American men.Journal of the National Cancer Institute · 2026Article
- Landscape of Allele-Specific Expression in Prostate Cancer Reveals Recurrent, Stage-Specific Events in AR Signaling and Resistance Pathways.Molecular cancer research : MCR · 2026Article
- A panel of four autoantibodies to tumour-associated antigens in patients with prostate cancer and its potential for multi-cancer detection.British journal of cancer · 2026Article
- Putative breast cancer risk variants from populations of South Asian ancestry are under-represented in public variant classification databases.Breast cancer research : BCR · 2026Article
- Review
- Investigating Genomic Differences by Ethnicity in Breast, Colorectal and Prostate Cancers: Secondary Data Analysis of the Genomic Data Commons (GDC) Database.Cancer medicine · 2025Article
- Deep Sequencing Reveals Novel Mutations inInternational journal of molecular sciences · 2025Article
- Nationwide Genomic Data Analysis of Japanese Prostate Cancer Patients From C-CAT Database.Cancer medicine · 2025Article
- Scaling for African Inclusion in High-Throughput Whole Cancer Genome Bioinformatic Workflows.Cancers · 2025Review
- Evaluation of human papillomavirus as a risk factor in prostate cancer pathogenesis.Discover oncology · 2025Review
- Heterozygous variants disrupting the interaction of ERF with activated ERK1/2 cause microcephaly, developmental delay, and skeletal anomalies.European journal of human genetics : EJHG · 2025Article
- The Germline and Somatic Origins of Prostate Cancer Heterogeneity.Cancer discovery · 2025Article
- A complex phylogeny of lineage plasticity in metastatic castration resistant prostate cancer.NPJ precision oncology · 2025Article
- Review
- Review
- The Emerging Predictive and Prognostic Role of Aggressive-Variant-Associated Tumor Suppressor Genes Across Prostate Cancer Stages.International journal of molecular sciences · 2025Review
- Exploring therapeutic applications ofFrontiers in oncology · 2025Review
- Epidemiologic study on prostate cancer in Sudanese men across African ethnic groups.Scientific reports · 2024Article
- Frequent CHD1 deletions in prostate cancers of African American men is associated with rapid disease progression.NPJ precision oncology · 2024Article
31 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 1 institution in 1 country.
Franklin W HuangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. levi_garraway@dfci.harvard.edu franklin_huang@dfci.harvard.edu ipowell@med.wayne.edu rubinma@med.cornell.edu.
Juan Miguel MosqueraCaryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine-New York Presbyterian, New York, New York.
Andrea GarofaloCancer Program, the Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Coyin OhCancer Program, the Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Maria BacoCancer Program, the Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Ali Amin-MansourCancer Program, the Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Bokang RabashaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Samira BahlCancer Program, the Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Stephanie A MullaneCancer Program, the Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Brian D RobinsonCaryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine-New York Presbyterian, New York, New York.
Saud AldubayanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Francesca KhaniDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York.
Beerinder KarirCaryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine-New York Presbyterian, New York, New York.
Eejung KimDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Jeremy Chimene-WeissCancer Program, the Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Matan HofreeCancer Program, the Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Alessandro RomanelCentre for Integrative Biology, University of Trento, Trento, Italy.
Joseph R OsborneCentre for Integrative Biology, University of Trento, Trento, Italy.
Jong Wook KimDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Gissou AzabdaftariDepartment of Pathology, Roswell Park Cancer Institute, Roswell Park, New York.
Anna Woloszynska-ReadDepartment of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Roswell Park, New York.
Karen SfanosDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Angelo M De MarzoDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Francesca DemichelisCaryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine-New York Presbyterian, New York, New York.
Stacey GabrielCancer Program, the Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Eliezer M Van AllenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Jill MesirovCancer Program, the Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Pablo TamayoCancer Program, the Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Mark A RubinCaryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine-New York Presbyterian, New York, New York. levi_garraway@dfci.harvard.edu franklin_huang@dfci.harvard.edu ipowell@med.wayne.edu rubinma@med.cornell.edu.
Isaac J PowellBarbara Ann Karmanos Cancer Institute, Detroit, Michigan. levi_garraway@dfci.harvard.edu franklin_huang@dfci.harvard.edu ipowell@med.wayne.edu rubinma@med.cornell.edu.
Levi A GarrawayDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. levi_garraway@dfci.harvard.edu franklin_huang@dfci.harvard.edu ipowell@med.wayne.edu rubinma@med.cornell.edu.
Harvard University · US
Funding
Large Scale Sequencing and Analysis of GenomesU54HG003067 · NHGRI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI GABRIEL, STACEY, LANDER, ERIC S · 2004 to 2015
$568.6MTwo-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MARK G FRATTINI · 1985 to 2026
$116.6MTraining and Career Development CoreU54CA132378 · NCI · CITY COLLEGE OF NEW YORK · PI Tim Alan Ahles, ADRIANA ESPINOSA · 2008 to 2026
$28.9MTraining and Career Development and Education CoreU54CA137788 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Daniel Alan Heller · 2008 to 2026
$28.1MThe Dana-Farber Cancer Institute Cancer Target Discovery and Development CenterU01CA176058 · NCI · DANA-FARBER CANCER INST · PI HAHN, WILLIAM C. · 2013 to 2021
$7.8MGENOMIC ANALYSIS OF MEDULLOBLASTOMASR01CA109467 · NCI · CHILDREN'S HOSPITAL BOSTON · PI MESIROV, JILL P., POMEROY, SCOTT LOREN · 2004 to 2015
$7.3MEpitomic Biomarkers of Prostate CancerU01CA111275 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHINNAIYAN, ARUL M, RUBIN, MARK A. · 2004 to 2015
$6.8MMolecular Signatures of Lethal and Indolent Prostate CancerR01CA116337 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI RUBIN, MARK A. · 2006 to 2016
$5.3MKnowledge-based Gene Expression Analysis for Biomedical and Cancer ResearchR01CA121941 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MESIROV, JILL P. · 2006 to 2016
$5.1MGenePattern Notebooks for Cancer ResearchU24CA194107 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MESIROV, JILL P. · 2015 to 2019
$2.8MMolecular Signatures to Characterize the Oncogenic State of Individual TumorsR01CA154480 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TAMAYO, PABLO · 2011 to 2015
$2.0MSystematic Genetic Characterization of African American Prostate CancerU01CA162148 · NCI · DANA-FARBER CANCER INST · PI GARRAWAY, LEVI A. · 2012 to 2015
$1.3MNCI NIH HHS P30 CA016056NCI NIH HHS R01 CA109467NCI NIH HHS R01 CA116337NCI NIH HHS R01 CA121941NCI NIH HHS R01 CA154480NCI NIH HHS U01 CA111275NCI NIH HHS U01 CA162148NCI NIH HHS U01 CA176058NCI NIH HHS U24 CA194107NCI NIH HHS U54 CA132378NCI NIH HHS U54 CA137788NHGRI NIH HHS U54 HG003067
Abstract
African-American men have the highest incidence of and mortality from prostate cancer. Whether a biological basis exists for this disparity remains unclear. Exome sequencing (
Indexed as
AnimalsBlack or African AmericanCell Line, TumorClass I Phosphatidylinositol 3-KinasesExomeExome SequencingHumansMaleMiceMutationProstatic NeoplasmsPTEN PhosphohydrolaseRepressor ProteinsClass I Phosphatidylinositol 3-KinasesERF protein, humanPIK3CA protein, humanPTEN PhosphohydrolasePTEN protein, humanRepressor Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.